Enzalutamide + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Hormone Sensitive Prostate Cancer
Conditions
Metastatic Hormone Sensitive Prostate Cancer
Trial Timeline
Mar 9, 2016 → Jul 31, 2024
NCT ID
NCT02677896About Enzalutamide + Placebo
Enzalutamide + Placebo is a phase 3 stage product being developed by Astellas Pharma for Metastatic Hormone Sensitive Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02677896. Target conditions include Metastatic Hormone Sensitive Prostate Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02677896 | Phase 3 | Completed |
| NCT02528643 | Phase 2 | Completed |
| NCT02294461 | Phase 3 | Completed |
| NCT02003924 | Phase 3 | Completed |
| NCT01212991 | Phase 3 | Completed |
| NCT00974311 | Phase 3 | Completed |
Competing Products
20 competing products in Metastatic Hormone Sensitive Prostate Cancer